Urokinase-type plasminogen activator soluble receptor (suPAR) assay in clinical routine: evaluation one year after its introduction in the high automation corelab of the A. Gemelli hospital.

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Keywords: automation systems; SARS-CoV-2; soluble urokinase plasminogen activator receptor; suPAR EN automation systems SARS-CoV-2 soluble urokinase plasminogen activator receptor suPAR e33 e35 3 12/22/22 20230201 NES 230201 To the Editor, Medical laboratories undergo a continuous quality improvement process to increase efficiency and customer satisfaction and answer and meet clinical requests. Biochemical monitoring of COVID-19 patients through biomarkers has become critical for assessing disease severity and progression, monitoring therapeutic intervention as well as making treatment decisions using a precision medicine approach [[3]]. [Extracted from the article]